OncoMatch/Clinical Trials/NCT06754267
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Is NCT06754267 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Venetoclax and Olverembatinib for precursor b-cell acute lymphoblastic leukemia.
Treatment: Venetoclax · Olverembatinib · Predinisone — Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Philadelphia chromosome positive (Ph+) ALL is defined as ALL with translocation between chromosomes 9 and 22. And t(9;22)(q34;q11) is the most common chromosomal abnormality in ALL. Before the emergence of TKI, the prognosis of Ph+ ALL was extremely poor, and the long-term survival rate was only 10%-35%. Ph+ ALL accounts for about 30% of adult ALL. In this study, the investigators propose a treatment approach that combines Venetoclax with Olverembatinib and Predinisone in Ph+ B-ALL adults. The study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR fusion
positive for Philadelphia chromosome (presence of t(9;22) and/or BCR::ABL1 positive and/or FISH positive)
Required: ABL1 fusion
positive for Philadelphia chromosome (presence of t(9;22) and/or BCR::ABL1 positive and/or FISH positive)
Disease stage
Excluded: Stage ACCELERATED PHASE OR BLAST CRISIS OF CHRONIC MYELOID LEUKEMIA
Accelerated phase or blast crisis of chronic myeloid leukemia [excluded]
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic anti-leukemia treatment
Exception: allowed pretreatment
Subjects who have received systemic anti-leukemia treatment (including but not limited to TKI, radiotherapy or chemotherapy, except for the allowed pretreatment)
Lab requirements
Kidney function
serum creatinine > 1.5 uln
Liver function
serum total bilirubin > 1.5 uln; alt or ast > 2.5 uln
Cardiac function
left ventricular ejection fraction (lvef) on echocardiography <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify